Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Hurler L, Szilágyi Á, Mescia F, Bergamaschi L, Mező B, Sinkovits G, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Csuka D, Kajdácsi E, Cervenak L, Kiszel P, Masszi T, Vályi-Nagy I, Würzner R; Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITII

Journal title: Frontiers in Immunology

Journal publisher: Frontiers Media S.A.

Published year: 2023

DOI identifier: 10.3389/fimmu.2023.1162171

ISSN: 1664-3224